A Study to Evaluate the Effect of MCI-186 at Therapeutic and Supra-Therapeutic Doses on the QT Interval(QT)/Corrected QT Interval(QTc) Interval in Healthy Subjects

Status:
Completed

Trial end date:
2018-10-23

Target enrollment:

Participant gender:

To evaluate the effect of MCI-186 on the QT interval corrected for heart rate using Fridericia's formula (QTcF)

Phase 1

Mitsubishi Tanabe Pharma Corporation

Edaravone